CTLA4 and neoplasm: Cadonilimab was the first PD-1 and CTLA-4 bispecific antibody inhibitor, and its unique molecular structure,Fc segment silencing, and the tumor-enrichment effect made it less prone to irAEs which might to some extent demonstrate the potential advantages of the cadonilimab compared to the CTLA-4 and PD-1 combination treatment regimen.